title: Targeting a metalloprotease-PAR1 signaling system with cell-penetrating pepducins inhibits angiogenesis, ascites, and progression of ovarian cancer.
abstract: Gene chip and proteomic analyses of tumors and stromal tissue has led to the identification of dozens of candidate tumor and host components potentially involved in tumor-stromal interactions, angiogenesis, and progression of invasive disease. In particular, matrix metalloproteases (MMP) have emerged as important biomarkers and prognostic factors for invasive and metastatic cancers. From an initial screen of benign versus malignant patient fluids, we delineated a metalloprotease cascade comprising MMP-14, MMP-9, and MMP-1 that culminates in activation of PAR1, a G protein-coupled protease-activated receptor up-regulated in diverse cancers. In xenograft models of advanced peritoneal ovarian cancer, PAR1-dependent angiogenesis, ascites formation, and metastasis were effectively inhibited by i.p. administration of cell-penetrating pepducins based on the intracellular loops of PAR1. These data provide an in vivo proof-of-concept that targeting the metalloprotease-PAR1 signaling system may be a novel therapeutic approach in the treatment of ovarian cancer.
authors.affiliation: Molecular Oncology Research Institute, Tufts Medical Center, Box 7510, Boston, MA 02111, USA.
authors.forename: Anika
authors.initials: A
authors.lastname: Agarwal
authors.forename: Lidija
authors.initials: L
authors.lastname: Covic
authors.forename: Leila M
authors.initials: LM
authors.lastname: Sevigny
authors.forename: Nicole C
authors.initials: NC
authors.lastname: Kaneider
authors.forename: Katherine
authors.initials: K
authors.lastname: Lazarides
authors.forename: Gissou
authors.initials: G
authors.lastname: Azabdaftari
authors.forename: Sheida
authors.initials: S
authors.lastname: Sharifi
authors.forename: Athan
authors.initials: A
authors.lastname: Kuliopulos
mesh_terms: D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology; D001201:Ascites / Q000201:enzymology*; D001826:Body Fluids / Q000201:enzymology; D045744:Cell Line, Tumor; D002465:Cell Movement / Q000187:drug effects; D018450:Disease Progression; D000077143:Docetaxel; D005260:Female; D005347:Fibroblasts / Q000187:drug effects / Q000201:enzymology; D006801:Humans; D045726:Metalloproteases / Q000037:antagonists & inhibitors*; D051379:Mice; D008819:Mice, Nude; D041681:NIH 3T3 Cells; D009361:Neoplasm Invasiveness; D009389:Neovascularization, Pathologic / Q000201:enzymology*; D009842:Oligopeptides / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000201:enzymology / Q000473:pathology*; D010537:Peritoneum / Q000201:enzymology / Q000473:pathology; D015398:Signal Transduction / Q000187:drug effects*; D043823:Taxoids / Q000008:administration & dosage / Q000494:pharmacology; D023041:Xenograft Model Antitumor Assays; D010975:Platelet Aggregation Inhibitors
chemical_list: D009842:Oligopeptides; D043823:Taxoids; D000077143:Docetaxel; D045726:Metalloproteases; D010975:Platelet Aggregation Inhibitors
references.citation: Cancer Cell. 2004 Jan;5(1):19-24
references.pmid: 14749123
references.citation: Nat Med. 2002 Oct;8(10):1161-5
references.pmid: 12357249
references.citation: J Biol Chem. 1996 Nov 22;271(47):30174-80
references.pmid: 8939968
references.citation: Gynecol Oncol. 2006 Mar;100(3):506-10
references.pmid: 16214204
references.citation: Genes Dev. 2006 Oct 1;20(19):2673-86
references.pmid: 16983145
references.citation: J Biol Chem. 2004 Dec 3;279(49):51148-55
references.pmid: 15381707
references.citation: Ann N Y Acad Sci. 1999 Jun 30;878:25-39
references.pmid: 10415718
references.citation: Nat Med. 1996 Apr;2(4):461-2
references.pmid: 8597958
references.citation: Cancer Res. 1998 Dec 1;58(23):5321-5
references.pmid: 9850057
references.citation: Int J Cancer. 2005 Jan 20;113(3):372-8
references.pmid: 15455382
references.citation: Annu Rev Cell Dev Biol. 2001;17:463-516
references.pmid: 11687497
references.citation: Endocr Relat Cancer. 2004 Jun;11(2):163-78
references.pmid: 15163296
references.citation: Proc Natl Acad Sci U S A. 1999 Oct 26;96(22):12257-62
references.pmid: 10535908
references.citation: J Pathol. 1998 Jul;185(3):256-61
references.pmid: 9771478
references.citation: Gynecol Oncol. 2000 Jun;77(3):369-76
references.pmid: 10831344
references.citation: Clin Cancer Res. 2005 Apr 1;11(7):2686-94
references.pmid: 15814650
references.citation: Nat Med. 1998 Aug;4(8):909-14
references.pmid: 9701242
references.citation: Nature. 2002 Jan 31;415(6871):530-6
references.pmid: 11823860
references.citation: Oncogene. 2003 Nov 27;22(54):8716-22
references.pmid: 14647466
references.citation: Cancer Res. 2001 Aug 1;61(15):5933-40
references.pmid: 11479236
references.citation: Gynecol Oncol. 2001 Aug;82(2):291-8
references.pmid: 11531282
references.citation: Science. 2002 Mar 29;295(5564):2387-92
references.pmid: 11923519
references.citation: J Cell Physiol. 1995 Jun;163(3):510-22
references.pmid: 7775594
references.citation: Nat Protoc. 2007;2(3):504-11
references.pmid: 17406614
references.citation: Biochemistry. 1999 Apr 6;38(14):4572-85
references.pmid: 10194379
references.citation: Cancer Res. 2006 Aug 1;66(15):7766-74
references.pmid: 16885380
references.citation: Cancer Res. 1995 Jan 15;55(2):360-8
references.pmid: 7812969
references.citation: Circulation. 2006 Mar 7;113(9):1244-54
references.pmid: 16505172
references.citation: Circ Res. 2003 Feb 21;92(3):272-8
references.pmid: 12595338
references.citation: Cell. 2005 Feb 11;120(3):303-13
references.pmid: 15707890
references.citation: J Cell Sci. 2007 Mar 15;120(Pt 6):921-8
references.pmid: 17344429
references.citation: Nat Med. 2005 Jun;11(6):661-5
references.pmid: 15880119
references.citation: Cancer Res. 2002 May 15;62(10):2923-8
references.pmid: 12019173
references.citation: J Biol Chem. 2003 Sep 19;278(38):36537-46
references.pmid: 12847101
references.citation: J Natl Cancer Inst. 2002 Aug 7;94(15):1134-42
references.pmid: 12165638
references.citation: Am J Pathol. 1998 Oct;153(4):1249-56
references.pmid: 9777956
references.citation: Gynecol Oncol. 2004 Dec;95(3):437-48
references.pmid: 15581944
references.citation: Int J Cancer. 1994 Jul 1;58(1):50-6
references.pmid: 8014015
references.citation: Nat Rev Cancer. 2002 Mar;2(3):161-74
references.pmid: 11990853
references.citation: Cancer Res. 2006 Mar 1;66(5):2658-65
references.pmid: 16510585
references.citation: Mol Cell Endocrinol. 2002 Feb 22;187(1-2):39-45
references.pmid: 11988310
references.citation: Proc Natl Acad Sci U S A. 2002 Jan 22;99(2):643-8
references.pmid: 11805322
references.citation: Cancer Cell. 2005 Mar;7(3):207-8
references.pmid: 15766657
references.citation: Cancer. 1997 Oct 15;80(8):1457-63
references.pmid: 9338470
references.citation: Nat Immunol. 2007 Dec;8(12):1303-12
references.pmid: 17965715
references.citation: Cancer Res. 2004 Oct 1;64(19):7045-9
references.pmid: 15466198
references.citation: Nat Med. 2005 May;11(5):481-3
references.pmid: 15864312
references.citation: N Engl J Med. 2006 Jan 5;354(1):34-43
references.pmid: 16394300